)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Seres Therapeutics (MCRB) investor relations material
Seres Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
SER-155 Phase 1b demonstrated a 77% relative risk reduction in bloodstream infections in allo-HSCT patients, with strong safety and FDA Breakthrough Therapy designation; Phase 2 protocol submitted and pending funding, with global KOL engagement and plans for broader patient populations.
Completed sale of VOWST business to Nestlé Health Science in September 2024, providing significant capital, streamlining operations, and extending cash runway into Q1 2026.
Company is actively pursuing partnerships, out-licensing, mergers, and other strategic transactions to secure capital for SER-155 and pipeline advancement.
Leadership transition: Eric Shaff resigned as CEO effective July 31, 2025; Marella Thorell and Thomas DesRosier appointed as Co-CEOs, with additional board changes.
Pipeline includes SER-147 for chronic liver disease and SER-603 for IBD, with preclinical and early clinical data supporting expansion.
Financial highlights
Net loss from continuing operations was $19.9M in Q2 2025, down from $26.2M in Q2 2024; net income for the first half of 2025 was $12.8M, driven by the VOWST sale.
R&D expenses decreased to $12.9M from $15.8M year-over-year, reflecting lower costs post-Phase 1b and reduced personnel expenses.
G&A expenses were $10.3M, down from $13.1M in Q2 2024, mainly due to lower personnel and IT costs.
Cash and cash equivalents stood at $45.4M as of June 30, 2025; cash runway expected to fund operations into Q1 2026.
VOWST asset sale generated $100M upfront, $15M equity investment, $60M prepaid milestone, and $275M in potential future milestones.
Outlook and guidance
Additional funding is required to initiate the SER-155 Phase 2 study; interim results expected within 12 months of study start, potentially informing a registrational trial.
Management is pursuing business development transactions, including partnerships, out-licensing, or mergers, to secure necessary capital.
Ongoing cost reduction actions to extend cash runway; evaluating further measures.
SER-155 Phase II interim data timeline?
What is the rationale for exploring mergers?
SER-155's potential in IREC?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Seres Therapeutics earnings date
Q3 202512 Nov, 2025
Next Seres Therapeutics earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Seres Therapeutics, Inc. is a microbiome therapeutics platform company that engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate which has completed Phase III clinical trial for the treatment of CDI. It also develops SER-155 and SER-287 which are in Phase Ib clinical trial to reduce incidences of gastrointestinal infections and ulcerative colitis; SER-301 that is in Phase Ib clinical trial to treat metastatic melanoma; and SER-262 to treat Clostridioides difficile infection.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage